Patents by Inventor Philip Chamberlain

Philip Chamberlain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 11733233
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 22, 2023
    Assignee: CELGENE CORPORATION
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • METHODS FOR SCREENING CEREBLON MODIFYING COMPOUNDS
    Publication number: 20220412953
    Abstract: A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
    Type: Application
    Filed: June 28, 2022
    Publication date: December 29, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Mary MATYSKIELA, Philip CHAMBERLAIN, Suzana Sturlini COUTO, Katherine STAMP, Philip J. SHERRATT, Gang LU, Julia HUI
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 11419861
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 23, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • Methods for screening cereblon modifying compounds
    Patent number: 11402372
    Abstract: A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mary Matyskiela, Philip Chamberlain, Suzana Sturlini Couto, Katherine Stamp, Philip J. Sherratt, Gang Lu, Julia Hui
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210003557
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210000813
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: April 17, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 10830762
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: November 10, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 10668057
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 2, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • METHODS FOR SCREENING CEREBLON MODIFYING COMPOUNDS
    Publication number: 20190219562
    Abstract: A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 18, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Mary Matyskiela, Philip Chamberlain, Suzana Sturlini Couto, Katherine Stamp, Philip J. Sherratt, Gang Lu, Julia Hui
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20190030019
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: July 30, 2018
    Publication date: January 31, 2019
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20190017998
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: December 27, 2016
    Publication date: January 17, 2019
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 10092555
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: October 9, 2018
    Assignee: CELGENE CORPORATION
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20150374678
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 31, 2015
    Inventors: Philip CHAMBERLAIN, Brian E. CATHERS, Antonia LOPEZ-GIRONA
  • Optical communication system
    Patent number: 8548326
    Abstract: An optical communication system is disclosed. The optical communication system includes a reflection hub connected to a plurality of communication modules. The communication modules communicate optical signals to one another via two way light channels, such that an optical signal is scattered off a diffuse surface at a distal end of the reflection hub and into the two way light channel of each communication module.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: October 1, 2013
    Assignee: Chrysler Group LLC
    Inventors: Brian R. Merrill, Philip Chamberlain
  • OPTICAL COMMUNICATION SYSTEM
    Publication number: 20120243867
    Abstract: An optical communication system is disclosed. The optical communication system includes a reflection hub connected to a plurality of communication modules. The communication modules communicate optical signals to one another via two way light channels, such that an optical signal is scattered off a diffuse surface at a distal end of the reflection hub and into the two way light channel of each communication module.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 27, 2012
    Inventors: Brian R Merrill, Philip Chamberlain
  • COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS
    Publication number: 20090306039
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
    Type: Application
    Filed: July 20, 2007
    Publication date: December 10, 2009
    Inventors: Shifeng Pan, Yi Liu, Yun Feng Xie, Dai Cheng, yongqin Wan, Dong Han, Yang Yang, Wenqi Gao, Jiqing Jiang, Badry Bursulaya, Philip Chamberlain, Donald Karanewsky, Xia Wang